Scarica l'app Stockscreener
4.92
3.53%
-0.18
Pre-mercato:
4.77
-0.15
-3.05%
Minerva Neurosciences Inc Borsa (NERV) Ultime notizie
Minerva Neurosciences, Inc.(NasdaqCM:NERV) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2500 Growth Benchmark - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2000 Index - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2000 Value Benchmark - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM:NERV) added to Russell Microcap Value Benchmark Index - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2000 Growth Benchmark - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 3000E Index - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell Microcap Index - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM:NERV) added to Russell 3000E Growth Benchmark - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 3000 Index - marketscreener.com
Price to sales forward of Minerva Neurosciences, Inc – NASDAQ:NERV - TradingView
Minerva Neurosciences Inc Actuals & Estimates (NASDAQ:NERV) - TradingView
NERV Forecast — Price Target — Prediction for 2027 - TradingView
Minerva Neurosciences Inc Actuals & Estimates (SWB:4MNA) - TradingView
Minerva Neurosciences Inc Actuals & Estimates (FWB:4MNA) - TradingView
ETFs Investing in Minerva Neurosciences Inc Stocks - TradingView
Minerva Neurosciences Inc Actuals & Estimates (BOATS:NERV) - TradingView
Minerva Neurosciences Inc (NERV) Valuation: PE, PB & Fair Value Analysis - TradingKey
4MNA Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Minerva Neurosciences, Inc – NASDAQ:NERV - TradingView
Price to book forward of Minerva Neurosciences, Inc – NASDAQ:NERV - TradingView
Minerva Neurosciences Inc (NERV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Minerva Neurosciences Inc (NERV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Minerva Neurosciences Inc (NERV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Minerva Neurosciences Inc (NERV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Minerva Neurosciences Inc (NERV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Minerva Neurosciences Inc (NERV) Institutional Confidence - TradingKey
Minerva Neurosciences Inc (NERV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Minerva Neurosciences Inc (NERV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Minerva Neurosciences (NERV) Holds Near Support After Modest Decline: Key Levels in FocusMutual Fund Flow - newsline.com
Minerva Neurosciences (NERV) CFO awarded 680,000 stock options at $4.6800 - Stock Titan
Minerva Neurosciences (NERV) CEO granted 1.69M stock options at $4.68 strike - Stock Titan
Minerva Neurosciences (NERV) grants director 50,000 stock options at $4.68 - Stock Titan
Minerva Neurosciences (NERV) director receives stock options for 50,000 shares - Stock Titan
Minerva Neurosciences grants 50,000 options to director | NERV Insider Trading - Stock Titan
Minerva Neurosciences director granted 50,000 options | NERV Insider Trading - Stock Titan
Minerva Neurosciences (NERV) awards 50,000 stock options to director - Stock Titan
Minerva Neurosciences (NERV) loses 37.5% in 4 weeks, here's why a trend reversal may be around the corner - MSN
NERV: Roluperidone targets negative symptoms in schizophrenia, with pivotal data expected in 2027 - TradingView
Minerva Neurosciences Updates Governance Following 2026 Shareholder Meeting - TipRanks
Minerva Neurosciences (NERV) holders approve officer shield, drop forum clause - Stock Titan
NERV Q1 2026 Earnings: Wider-than-Expected Loss Highlights Ongoing Development CostsHealthcare Earnings Report - newsline.com
Minerva Neurosciences Establishes Scientific Advisory Board - GlobeNewswire
Minerva Neurosciences (NERV) Holds Near Support After Slight Decline: Key Levels to WatchSMA Signal - thelegaladvocate.com
Minerva Neurosciences Announces Sales Agreement with Leerink Partners for Common Stock Offering (Form 8-K Filing) - Minichart
Minerva Neurosciences (NERV) Edges Lower Near Support Level Amid Quiet TradingOBV Breakout - newsline.com
Minerva Neurosciences Launches ATM Offering to Fund Trial - TipRanks
Minerva Neurosciencesto offer and sell up to $75 million in common stock through Leerink Partners - marketscreener.com
Minerva Neurosciences (NERV) adds $75M ATM program and lengthens key Phase 3 C19 trial - Stock Titan
Minerva Neurosciences (NASDAQ: NERV) launches $75M at‑the‑market stock program - Stock Titan
Minerva Neurosciences Inc (NERV) Q1 2026 Earnings: Wider Loss Highlights Ongoing Pre-Revenue Development StageDownward Estimate Revision - Newser
Minerva Neurosciences Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Faces Challenges - Newser
All you need to know about Minerva Neurosciences (NERV) rating upgrade to buy - MSN
Minerva Neurosciences Q1 2026 Earnings: EPS Misses Street Estimates, Stock Gains on Pipeline OptimismPost-Earnings Drift - Newser
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy - Yahoo Finance
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference - Investing News Network
0.05%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):